Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene) thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling

Organic and Biomolecular Chemistry

Volumn 11, Issue 22, 2013, Pages 3706-3732

  Jung, Kwan Young ^a   Samadani, Ramin ^a   Chauhan, Jay ^a   Nevels, Kerrick ^a   Yap, Jeremy L ^a   Zhang, Jun ^a   Worlikar, Shilpa ^a   Lanning, Maryanna E ^a   Chen, Lijia ^a   Ensey, Mary ^b   Shukla, Sagar ^a   Salmo, Rosene ^c   Heinzl, Geoffrey ^a   Gordon, Caryn ^d   Dukes, Troy ^e   MacKerell, Alexander D ^a,f   Shapiro, Paul ^a,f   Fletcher, Steven ^a,f  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NOTRE DAME OF MARYLAND UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e Antioch Diploma Plus High School   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SIGNALING; DERMATOLOGY;

MELANOMA CELLS; PHARMACOPHORES; STRUCTURAL MODIFICATIONS; THIAZOLIDINES;

ONCOLOGY;

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3-(2-AMINOETHYL)-5-(4-ETHOXYBENZYLIDENE)THIAZOLIDINE-2,4-DIONE; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE;

ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HELA CELL LINE; HUMAN; MELANOMA; METABOLISM; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HELA CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES;

EID: 84877735346     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/c3ob40199e     Document Type: Article

References (48)

1. K. Burkhard S. Smith R. Deshmukh A. D. MacKerell, Jr. P. Shapiro Development of extracellular signal-regulated kinase inhibitors Curr. Top. Med. Chem. 2009 9 8 678 689
2. T. S. Lewis P. S. Shapiro N. G. Ahn Signal transduction through MAP kinase cascades Adv. Cancer Res. 1998 74 49 139
3. A. von Kriegsheim D. Baiocchi M. Birtwistle D. Sumpton W. Bienvenut N. Morrice K. Yamada A. Lamond G. Kalna R. Orton D. Gilbert W. Kolch Cell fate decisions are specified by the dynamic ERK interactome Nat. Cell Biol. 2009 11 12 1458 1464
4. C. W. Reuter M. A. Morgan L. Bergmann Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000 96 5 1655 1669
5. M. S. Brose P. Volpe M. Feldman M. Kumar I. Rishi R. Gerrero E. Einhorn M. Herlyn J. Minna A. Nicholson J. A. Roth S. M. Albelda H. Davies C. Cox G. Brignell P. Stephens P. A. Futreal R. Wooster M. R. Stratton B. L. Weber BRAF and RAS mutations in human lung cancer and melanoma Cancer Res. 2002 62 23 6997 7000
6. J. L. Bos ras Oncogenes in human cancer: a review Cancer Res. 1989 49 17 4682 4689
7. H. Davies G. R. Bignell C. Cox P. Stephens S. Edkins S. Clegg J. Teague H. Woffendin M. J. Garnett W. Bottomley N. Davis E. Dicks R. Ewing Y. Floyd K. Gray S. Hall R. Hawes J. Hughes V. Kosmidou A. Menzies C. Mould A. Parker C. Stevens S. Watt S. Hooperd R. Wilson H. Jayatilake B. A. Gusterson C. Cooper J. Shipley D. Hargrave K. Pritchard-Jones N. Maitland G. Chenevix-Trench G. J. Riggins D. D. Bigner G. Palmieri A. Cossu A. Flanagan A. Nicholson J. W. Ho S. Y. Leung S. T. Yuen B. L. Weber H. F. Seigler T. L. Darrow H. Paterson R. Marais C. J. Marshall R. Wooster M. R. Stratton P. A. Futreal Mutations of the BRAF gene in human cancer Nature 2002 417 6892 949 954
8. J. Mendelsohn J. Baselga Epidermal growth factor receptor targeting in cancer Semin. Oncol. 2006 33 4 369 385
9. W. Kolch A. Kotwaliwale K. Vass P. Janosch The role of Raf kinases in malignant transformation Expert Rev. Mol. Med. 2002 4 8 1 18
10. L. O. Murphy S. Smith R. H. Chen D. C. Fingar J. Blenis Molecular interpretation of ERK signal duration by immediate early gene products Nat. Cell Biol. 2002 4 8 556 564
11. S. M. Wilhelm C. Carter L. Tang D. Wilkie A. McNabola H. Rong C. Chen X. Zhang P. Vincent M. McHugh Y. Cao J. Shujath S. Gawlak D. Eveleigh B. Rowley L. Liu L. Adnane M. Lynch D. Auclair I. Taylor R. Gedrich A. Voznesensky B. Riedl L. E. Post G. Bollag P. A. Trail BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 2004 64 19 7099 7109
12. T. B. Lowinger B. Riedl J. Dumas R. A. Smith Design and discovery of small molecules targeting raf-1 kinase Curr. Pharm. Des. 2002 8 25 2269 2278
13. N. M. Appels J. H. Beijnen J. H. Schellens Development of farnesyl transferase inhibitors: a review Oncologist 2005 10 8 565 578
14. A. Willems K. Gauger C. Henrichs N. Harbeck Antibody therapy for breast cancer Anticancer Res. 2005 25 3A 1483 1489
15. B. B. Friday A. A. Adjei Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy Clin. Cancer Res. 2008 14 2 342 346
16. A. Arora E. M. Scholar Role of tyrosine kinase inhibitors in cancer therapy J. Pharmacol. Exp. Ther. 2005 315 3 971 979
17. J. L. Yap S. Worlikar A. D. MacKerell, Jr. P. Shapiro S. Fletcher Small-molecule inhibitors of the ERK signaling pathway: towards novel anticancer therapeutics ChemMedChem 2011 6 1 38 48
18. Y. N. Gopal W. Deng S. E. Woodman K. Komurov P. Ram P. D. Smith M. A. Davies Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells Cancer Res. 2010 70 21 8736 8747
19. D. E. Goggin K. J. Steadman R. J. Emery S. C. Farrow R. L. Benech-Arnold S. B. Powles ABA inhibits germination but not dormancy release in mature imbibed seeds of Lolium rigidum Gaud J. Exp. Bot. 2009 60 12 3387 3396
20. J. Meng H. Peng B. Dai W. Guo L. Wange L. Ji J. D. Minna C. M. Chresta P. D. Smith B. Fang J. A. Roth High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) Cancer Biol. Ther. 2009 8 21 2073 2080
21. J. A. McCubrey L. S. Steelman W. H. Chappell S. L. Abrams E. W. Wong F. Chang B. Lehmann D. M. Terrian M. Milella A. Tafuri F. Stivala M. Libra J. Basecke C. Evangelisti A. M. Martelli R. A. Franklin Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim. Biophys. Acta 2007 1773 8 1263 1284
22. B. N. Rexer J. A. Engelman C. L. Arteaga Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists Cell Cycle 2009 8 1 18 22
23. F. Morgillo F. Cantile M. Fasano T. Troiani E. Martinelli F. Ciardiello Resistance mechanisms of tumour cells to EGFR inhibitors Clin. Transl. Oncol. 2009 11 5 270 275
24. P. I. Poulikakos C. Zhang G. Bollag K. M. Shokat N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 2010 464 7287 427 430
25. J. Tsai J. T. Lee W. Wang J. Zhang H. Chod S. Mamo R. Bremer S. Gillette J. Kong N. K. Haass K. Sproesser L. Li K. S. Smalley D. Fong Y. L. Zhu A. Marimuthu H. Nguyen B. Lam J. Liu I. Cheung J. Rice Y. Suzuki C. Luu C. Settachatgul R. Shellooe J. Cantwell S. H. Kim J. Schlessinger K. Y. Zhang B. L. West B. Powell G. Habets C. Zhang P. N. Ibrahim P. Hirth D. R. Artis M. Herlyn G. Bollag Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U. S. A. 2008 105 8 3041 3046
26. C. M. Johannessen J. S. Boehm S. Y. Kim S. R. Thomas L. Wardwell L. A. Johnson C. M. Emery N. Stransky A. P. Cogdill J. Barretina G. Caponigro H. Hieronymus R. R. Murray K. Salehi-Ashtiani D. E. Hill M. Vidal J. J. Zhao X. Yang O. Alkan S. Kim J. L. Harris C. J. Wilson V. E. Myer P. M. Finan D. E. Root T. M. Roberts T. Golub K. T. Flaherty R. Dummer B. L. Weber W. R. Sellers R. Schlegel J. A. Wargo W. C. Hahn L. A. Garraway COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 2010 468 7326 968 972
27. F. Chen C. N. Hancock A. T. Macias J. Joh K. Still S. Zhong A. D. MacKerell, Jr. P. Shapiro Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure Bioorg. Med. Chem. Lett. 2006 16 24 6281 6287
28. C. N. Hancock A. Macias E. K. Lee S. Y. Yu A. D. Mackerell, Jr. P. Shapiro Identification of novel extracellular signal-regulated kinase docking domain inhibitors J. Med. Chem. 2005 48 14 4586 4595
29. A. D. Sharrocks S. H. Yang A. Galanis Docking domains and substrate-specificity determination for MAP kinases Trends Biochem. Sci. 2000 25 9 448 453
30. T. Tanoue M. Adachi T. Moriguchi E. Nishida A conserved docking motif in MAP kinases common to substrates, activators and regulators Nat. Cell Biol. 2000 2 2 110 116
31. T. Tanoue R. Maeda M. Adachi E. Nishida Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions EMBO J. 2001 20 3 466 479
32. A. T. Macias M. Y. Mia G. Xia J. Hayashi A. D. MacKerell, Jr. Lead validation and SAR development via chemical similarity searching, application to compounds targeting the pY+3 site of the SH2 domain of p56lck J. Chem. Inf. Model. 2005 45 6 1759 1766
33. Q. Li A. Al-Ayoubi T. Guo H. Zheng A. Sarkar T. Nguyen S. T. Eblen S. Grant G. E. Kellogg S. Zhang Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors Bioorg. Med. Chem. Lett. 2009 19 21 6042 6046
34. Q. Li J. Wu H. Zheng K. Liu T. L. Guo Y. Liu S. T. Eblen S. Grant S. Zhang Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4- dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways Bioorg. Med. Chem. Lett. 2010 20 15 4526 4530
35. Y. N. Gopal W. Deng S. E. Woodman K. Komurov P. Ram P. D. Smith M. A. Davies Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells Cancer Res. 2010 70 21 8736 8747
36. P. I. Poulikakos N. Rosen Mutant BRAF melanomas-dependence and resistance Cancer Cell 2011 19 1 11 15
37. J. Wesierska-Gadek M. Gueorguieva O. Komina G. Schmid M. P. Kramer Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context J. Cell. Biochem. 2008 103 5 1607 1620
38. K. S. Iwamoto T. Mizuno T. Ito N. Tsuyama S. Kyoizumi T. Seyama Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival Cancer Res. 1996 56 17 3862 3865
39. D. Wolf V. Rotter Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells Proc. Natl. Acad. Sci. U. S. A. 1985 82 3 790 794
40. O. N. Ikediobi H. Davies G. Bignell S. Edkins C. Stevens S. O'Meara T. Santarius T. Avis S. Barthorpe L. Brackenbury G. Buck A. Butler J. Clements J. Cole E. Dicks S. Forbes K. Gray K. Halliday R. Harrison K. Hills J. Hinton C. Hunter A. Jenkinson D. Jones V. Kosmidou R. Lugg A. Menzies T. Mironenko A. Parker J. Perry K. Raine D. Richardson R. Shepherd A. Small R. Smith H. Solomon P. Stephens J. Teague C. Tofts J. Varian T. Webb S. West S. Widaa A. Yates W. Reinhold J. N. Weinstein M. R. Stratton P. A. Futreal R. Wooster Mutation analysis of 24 known cancer genes in the NCI-60 cell line set Mol. Cancer Ther. 2006 5 11 2606 2612
41. W. A. Loughlin J. D. Tyndall M. P. Glenn T. A. Hill D. P. Fairlie Update 1 of: beta-strand mimetics Chem. Rev. 2010 110 6 PR32 PR69
42. A. M. Aronov C. Baker G. W. Bemis et al., Flipped out: structure-guided of selective pyrazolylpyrrole ERK inhibitors J. Med. Chem. 2007 50 1280 1287
43. R. A. Hipskind D. Buscher A. Nordheim M. Baccarini Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors Genes Dev. 1994 8 15 1803 1816
44. R. H. Chen P. C. Juo T. Curran J. Blenis Phosphorylation of c-Fos at the C-terminus enhances its transforming activity Oncogene 1996 12 7 1493 1502
45. J. A. Frost H. Steen P. Shapiro T. Lewis N. Ahn P. E. Shaw M. H. Cobb Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins EMBO J. 1997 16 21 6426 6438
46. D. Schadendorf Peroxisome proliferator-activating receptors: a new way to treat melanoma? J. Invest. Dermatol. 2009 129 5 1061 1063
47. G. Hatzivassiliou B. Liu C. O'Brien J. M. Spoerke K. P. Hoeflich P. M. Haverty R. Soriano W. F. Forrest S. Heldens H. Chen K. Toy C. Ha W. Zhou K. Song L. S. Friedman L. C. Amler G. M. Hampton J. Moffat M. Belvin M. R. Lackner ERK inhibition overcomes acquired resistance to MEK inhibitors Mol. Cancer Ther. 2012 11 5 1143 1154
48. S. R. Boston R. Deshmukh S. Strome U. D. Priyakumar A. D. MacKerell, Jr. P. Shapiro Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9 BMC Cancer 2011 11 7